Navigation Links
Charleston Laboratories, Inc. Announces Senior Global Regulatory Hire
Date:2/15/2017

JUPITER, Fla., Feb. 15, 2017 /PRNewswire/ -- Charleston Laboratories, Inc. announced today that Mark A. Mannebach, Ph.D., R.Ph has joined its team as its Vice President of Global Regulatory Affairs & Quality Assurance.  In his role, Mark will oversee and manage all regulatory submissions and renewals and will be responsible for developing the technical requirements of supply and quality agreements and other external contracts, specifically in relation to Charleston Laboratories' pipeline of products that address unmet needs such as Opioid-Induced Nausea and Vomiting (OINV) and Migraine-Induced Nausea and Vomiting (MINV), including co-promotion activities under its collaboration with Daiichi Sankyo.

"We're proud to add Mark to our already impressive senior leadership team," said Mr. Paul Bosse, President and Chief Executive Officer at Charleston Laboratories.  "Mark's experience in regulatory and quality, coupled with his experience in the pain management industry, will make him a key member of the team."

Mark has more than 30 years of experience in the pharmaceutical industry in a variety of leadership roles at various major pharmaceutical companies including Parke-Davis/Warner-Lambert, Pharmacia, Baxter and Pfizer. For the past 8 years, Mark was the Vice President of Global Regulatory Affairs at Mallinckrodt where he spent a significant amount of his time overseeing the pain management portfolio.  Mark has extensive experience working with the Division of Anesthesia, Analgesia, and Addiction Products (DAAAP) on a number of NDAs including 505(b)(2) applications.  Mark had responsibility for the NDAs for the approved pain products Exalgo, Pennsaid (both 1.5% & 2% topical solutions), Xartemis XR, and Ofirmev.

"I was intrigued by the opportunity that Charleston Laboratories' pipeline and commercial strategy provides me professionally, to continue working in pain management," stated Dr. Mannebach.  "I'm honored to join a team with such deep experience and a commitment to clinical and commercial excellence."

About Charleston Laboratories, Inc.
Charleston Laboratories, Inc. is a privately held, specialty pharmaceutical company focused on the research, development and commercialization of novel pain products to prevent the burdensome side effects related to opioid analgesics and other analgesic products.  In August 2014, the Company entered a strategic collaboration with Daiichi Sankyo for the development and U.S. commercialization of Charleston Laboratories' investigational hydrocodone-based products, including its lead candidate CL-108.

Charleston Laboratories' product pipeline seeks to address unmet needs in Opioid-Induced Nausea and Vomiting (OINV), Postoperative Nausea and Vomiting (PONV), Chemotherapy-Induced Nausea and Vomiting (CINV), Radiation-Induced Nausea and Vomiting (RINV), and Migraine-Induced Nausea and Vomiting (MINV).  Charleston Laboratories intends to introduce novel pain therapies that reduce the burdensome side effects related to opioid analgesics and other products. For more information, please visit www.charlestonlabs.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/charleston-laboratories-inc-announces-senior-global-regulatory-hire-300407320.html


'/>"/>
SOURCE Charleston Laboratories, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Receive Complete Response Letter from FDA for New Drug Application for CL-108 (hydrocodone, acetaminophen, promethazine) Tablets for Oral Use
2. AAIPharma Services Corp. / Cambridge Major Laboratories, Inc. kondigt uitbreiding mogelijkheden en capaciteiten voor steriele productie medicijnen in Charleston, SC aan
3. AAIPharma Services Corp. / Cambridge Major Laboratories, Inc. Announces Expanded Capabilities and Capacity for Sterile Drug Product Manufacturing in Charleston, SC
4. The Business Development Board of Palm Beach Plays Key Role in Charleston Laboratories, Inc. Expansion
5. Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Announce Phase 3 Study of CL-108 Met Primary Endpoints
6. Charleston Area Medical Center Integrates Smart Pump Technology to Advance Patient Safety
7. Charleston Laboratories, Inc. Announces Completion of a Second Phase 3 Clinical Trial on its Lead Product, CL-108, and the Appointment of Dr. Raymond Dionne to its Scientific Advisory Board
8. Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charlestons Second Product, CL-H1T
9. Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Announce Three Poster Presentations at American Pain Society Annual Meeting
10. Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Announce Completion of a Pharmacokinetics Study on CL-108
11. Charleston Laboratories, Inc. Announces Key Clinical Updates for Novel Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... MARLBOROUGH, Mass., May 10, 2017 Hologic, Inc. ... financial results for the fiscal second quarter ended April ... (EPS) of $1.84 increased 666.7% compared to the prior ... business resulted in a significant gain, while non-GAAP diluted ... increased 3.2%, or 3.8% in constant currency terms.  Excluding ...
(Date:5/10/2017)... Md. , May 10, 2017 CSSi, ... solutions for the clinical research industry, is proud to ... www.CSSiEnroll.com . The new website features both enriched content ... user experience and enhances the company,s already well-established position ... industry. "After many months of hard ...
(Date:5/9/2017)... 9, 2017  Semler Scientific, Inc. (OTCQB: SMLR), ... to improve the clinical effectiveness and efficiency of ... first quarter ended March 31, 2017. ... customers to identify when preventive care options are ... like heart attacks or strokes occur," said ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... May 26, 2017 , ... Water damage to the flooring of several ... had left education officials with a number of critical issues to address before students ... to be accomplished with little or no disruption to class schedules. Second, the project ...
(Date:5/24/2017)... ... May 24, 2017 , ... In modern research, success depends ... instruments for research and understanding the basic principles that were designed to drive ... innovations in stereo microscopy for brightfield and fluorescence typically used in laboratories working ...
(Date:5/24/2017)... ... 24, 2017 , ... Altec Products, Inc., a leader in enterprise ... one-day technology conference in San Diego, CA. , At nVerge 2017, Altec will ... utilize and enhance their Sage ERP solutions by providing improved visibility and control to ...
(Date:5/24/2017)... ... May 24, 2017 , ... Drs. ... NY, who have now spent 10 years as clinical instructors for the reputable ... College of Dentistry. Through the program, private practitioners receive cutting-edge clinical training and ...
(Date:5/24/2017)... ... , ... Patients who want to receive cosmetic dentistry procedures such as Invisalign® ... for a consultation, with or without a referral. Dr. Bedich enjoys improving the appearance ... , Dr. Bedich offers a variety of cosmetic dentistry services at his practice that ...
Breaking Medicine News(10 mins):